Patents by Inventor Yasuhiko Tabata

Yasuhiko Tabata has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9132203
    Abstract: There is provided a gelatin-ICG complex that can suppress leakage of ICG included therein. The complex has a gelatin derivative including at least one of a phospholipid covalently bonded to a gelatin or a cholesterol covalently bonded to a gelatin, and indocyanine green.
    Type: Grant
    Filed: April 17, 2014
    Date of Patent: September 15, 2015
    Assignee: Canon Kabushiki Kaisha
    Inventors: Yasuhiko Tabata, Masato Minami, Yoshinori Tomida, Satoshi Yuasa, Tetsuya Yano, Jun-ichiro Jo, Mie Morita
  • Patent number: 9107953
    Abstract: An object of the present invention is to provide a sustained release composition containing SDF-1. The present invention provides a sustained release composition containing (1) SDF-1 and (2) a hydrogel containing modified gelatin having a carboxyl group and/or a sulfo group. Since the composition can release SDF-1, a chemokine which is a capable of promoting accumulation of vascular progenitor cells in vivo, in the sustained manner, it can be useful for treatment and/or suppression of symptom progression of ischemic disease or bone disease, as pharmaceutical preparations in various formulations.
    Type: Grant
    Filed: February 20, 2013
    Date of Patent: August 18, 2015
    Assignees: Ono Pharmaceutical Co., Ltd.
    Inventor: Yasuhiko Tabata
  • Patent number: 9040070
    Abstract: The present invention relates to a material for induction of hard tissue regeneration, comprising platelet-rich plasma and gelatin ?-TCP sponge, which promotes angiogenesis, osteogenesis, chondrogenesis and the like.
    Type: Grant
    Filed: October 19, 2010
    Date of Patent: May 26, 2015
    Assignee: Nitto Denko Corporation
    Inventors: Shinichi Okamoto, Yasuhiko Tabata
  • Patent number: 8895508
    Abstract: The present invention aims to provide a corneal endothelium cell proliferation accelerator and a therapeutic agent for a disease relating to corneal endothelium damage, which are administered into the anterior chamber. bFGF is released in a sustained manner by forming bFGF sustained-release gelatin hydrogel particles wherein bFGF is carried on gelatin hydrogel. Therefore, the proliferation of corneal endothelium cells can be accelerated persistently by administration of a preparation containing the bFGF sustained-release gelatin hydrogel particles into the anterior chamber, and diseases relating to corneal endothelium damage can be treated.
    Type: Grant
    Filed: July 24, 2009
    Date of Patent: November 25, 2014
    Assignees: Senju Pharmaceutical Co., Ltd.
    Inventors: Yasuhiko Tabata, Shigeru Kinoshita, Noriko Koizumi, Yuji Sakamoto, Naoki Okumura, Hiroaki Takahashi
  • Patent number: 8877158
    Abstract: It is an object of the present invention to provide a targeting agent that enables drug delivery to a neovascular site and the imaging of such a neovascular site, utilizing the effect of the agent to accumulate in the neovascular site. The present invention provides a targeting agent to a neovascular site, which comprises a gelatin-like protein.
    Type: Grant
    Filed: June 11, 2010
    Date of Patent: November 4, 2014
    Assignees: FUJIFILM Corporation, Kyoto University
    Inventors: Kentaro Nakamura, Yasuhiko Tabata
  • Publication number: 20140227195
    Abstract: There is provided a gelatin-ICG complex that can suppress leakage of ICG included therein. The complex has a gelatin derivative including at least one of a phospholipid covalently bonded to a gelatin or a cholesterol covalently bonded to a gelatin, and indocyanine green.
    Type: Application
    Filed: April 17, 2014
    Publication date: August 14, 2014
    Applicant: CANON KABUSHIKI KAISHA
    Inventors: Yasuhiko Tabata, Masato Minami, Yoshinori Tomida, Satoshi Yuasa, Tetsuya Yano, Jun-ichiro Jo, Mie Morita
  • Patent number: 8771734
    Abstract: A sustained-release preparation is provided which comprises a drug and a bioabsorbable polymer hydrogel, wherein a concentration gradient of the drug is formed in the hydrogel. Also disclosed is a method of sustained release of a drug in vivo using the sustained-release preparation of the invention. The directionality of the drug release may be controlled by employing the sustained-release preparation of the invention. The sustained-release preparation of the invention is particularly useful as an anti-cancer agent.
    Type: Grant
    Filed: March 15, 2004
    Date of Patent: July 8, 2014
    Assignee: Medgel Corporation
    Inventor: Yasuhiko Tabata
  • Patent number: 8753608
    Abstract: There is provided a gelatin-ICG complex that can suppress leakage of ICG included therein. The complex has a gelatin derivative including at least one of a phospholipid covalently bonded to a gelatin or a cholesterol covalently bonded to a gelatin, and indocyanine green.
    Type: Grant
    Filed: August 15, 2011
    Date of Patent: June 17, 2014
    Assignee: Canon Kabushiki Kaisha
    Inventors: Yasuhiko Tabata, Masato Minami, Yoshinori Tomida, Satoshi Yuasa, Tetsuya Yano, Jun-ichiro Jo, Mie Morita
  • Patent number: 8673638
    Abstract: The present invention relates to a cell culture support for culturing mesenchymal stem cells, which includes en upper surface including a plurality of wells, in which the upper surface has a root mean square roughness Rq of 100 to 280 nm and a linear density of 1.6 to 10 per 1 ?m length.
    Type: Grant
    Filed: August 5, 2011
    Date of Patent: March 18, 2014
    Assignee: Covalent Materials Corporation
    Inventors: Fumihiko Kitagawa, Takafumi Imaizumi, Shunsuke Takei, Itsuki Yamamoto, Yasuhiko Tabata
  • Publication number: 20140017171
    Abstract: An iron oxide particle constituting a Resovist (trademark) absorbs a small quantity of light in a near infrared region and emits a weak photoacoustic signal. According to a particle having a catechol-like compound and iron atoms, the particle having a ratio of the number of moles of the catechol-like compound to the number of moles of the iron atoms of 270/10,000 or more, light absorption in the near infrared region increases and a strong photoacoustic signal can be transmitted.
    Type: Application
    Filed: June 25, 2013
    Publication date: January 16, 2014
    Inventors: Yasuhiko Tabata, Sachiko Yamauchi, Mayuko Kishi, Masato Minami, Mika Yamagata, Satoshi Yuasa, Tetsuya Yano
  • Publication number: 20140017722
    Abstract: The present invention provides a hematopoietic stem cell identification probe.
    Type: Application
    Filed: July 10, 2013
    Publication date: January 16, 2014
    Inventors: Kohei Watanabe, Tsuyoshi Nomoto, Mie Okano, Taichi Shintou, Takeshi Miyazaki, Yasuhiko Tabata, Hiroshi Kohara
  • Publication number: 20130289254
    Abstract: An object of the present invention is to provide a cell-adhesive material for biological tissues, in which the surface of a material for biological tissues (particularly metallic material) is modified strongly with a large amount of a cell-adhesive artificial peptide (P) that retains a biological activity. The present invention provides a cell-adhesive material for biological tissues including a cell-adhesive artificial peptide (P) and a material for biological tissues, wherein the cell-adhesive artificial peptide (P) is immobilized on the surface of the material for biological tissues through an electrochemical reaction. The cell-adhesive artificial peptide (P) is preferably a peptide (P1) that is synthesized by a genetic recombinant microorganism and has at least one cell-adhesive minimal amino acid sequence (X) in one molecule. The number of the cell-adhesive minimal amino acid sequences (X) in one molecule of the polypeptide (P1) is preferably 3 to 50.
    Type: Application
    Filed: November 1, 2011
    Publication date: October 31, 2013
    Applicants: SANYO CHEMICAL INDUSTRIES, LTD.
    Inventors: Yasuhiko Tabata, Shingo Kawabata
  • Publication number: 20130266620
    Abstract: The present invention aims to provide a medical material which is safe for the live body, has high biocompatibility and is useful for promotion of cell differentiation. The present invention produces a medical material for promoting cell differentiation, which contains polyamino acid as a main component, wherein the polyamino acid contains at least one kind of amino acid residue selected from the group consisting of an alanine residue, a valine residue, a leucine residue, an isoleucine residue, a phenylalanine residue, a glycine residue, a glutamine residue, an aspartic acid residue optionally containing a protecting group in the side chain, a tyrosine residue optionally containing a protecting group in the side chain, a tryptophan residue optionally containing a protecting group in the side chain, a lysine residue optionally containing a protecting group in the side chain, and a glutamic acid residue optionally containing a protecting group in the side chain.
    Type: Application
    Filed: June 6, 2013
    Publication date: October 10, 2013
    Inventors: Manabu Kitazawa, Satoru Ohashi, Yoko Masuzawa, Kousaku Ohkawa, Yasuhiko Tabata
  • Publication number: 20130251636
    Abstract: Intended is to provide an MRI contrast agent that tends not to be phagocytized by reticuloendothelial cells and that has improved dispersion stability. The present invention is an MRI contrast agent containing composite particles, wherein the composite particles are those with polymer graft chains bound to surfaces of microparticles at a very high density sufficient to allow steric repulsion to occur between the graft chains, the micoparticles are inorganic microparticles that exhibit superparamagnetism, and the polymer graft chains have a number average molecular weight (Mn) of at least 30,000. Preferably, the MRI contrast agent is for tumor diagnosis.
    Type: Application
    Filed: September 29, 2011
    Publication date: September 26, 2013
    Applicants: KYOTO UNIVERSITY, KANEKA CORPORATION
    Inventors: Yoshiyuki Tago, Shinichi Yoshida, Kohji Ohno, Yoshinobu Tsujii, Yasuhiko Tabata
  • Publication number: 20130243824
    Abstract: An object of the present invention is to provide a sustained release composition containing SDF-1. The present invention provides a sustained release composition containing (1) SDF-1 and (2) a hydrogel containing modified gelatin having a carboxyl group and/or a sulfo group. Since the composition can release SDF-1, a chemokine which is a capable of promoting accumulation of vascular progenitor cells in vivo, in the sustained manner, it can be useful for treatment and/or suppression of symptom progression of ischemic disease or bone disease, as pharmaceutical preparations in various formulations.
    Type: Application
    Filed: February 20, 2013
    Publication date: September 19, 2013
    Applicants: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Ono Pharmaceutical Co., Ltd., Yasuhiko Tabata
  • Publication number: 20130157303
    Abstract: A biological substance which can enhance the proliferation and differentiation of cells; a method for evaluating the proliferation and differentiation of cells, which targets the biological substance; a composition for detecting the proliferation and differentiation of cells, which contains a molecule capable of binding to the biological substance; and a composition for enhancing the proliferation and differentiation of cells, which contains the biological substance. A part of a sulfated polysaccharide secreted from cells binds to a growth factor during the course of the proliferation and differentiation of the cells, that the amount of the sulfated polysaccharide capable of the above-mentioned binding and secreted from the cells correlates strongly with the progression of the proliferation and differentiation of the cells, and that the proliferation and differentiation of cells can be evaluated and the proliferation and differentiation of cells can be enhanced utilizing the sulfated polysaccharide.
    Type: Application
    Filed: August 31, 2011
    Publication date: June 20, 2013
    Applicants: Yasuhiko TABATA, SUMITOMO BAKELITE CO., LTD.
    Inventors: Yoshiaki Fukunishi, Yasuhiko Tabata
  • Patent number: 8435953
    Abstract: An object of the present invention is to provide a sustained release composition containing SDF-1. The present invention provides a sustained release composition containing (1) SDF-1 and (2) a hydrogel containing modified gelatin having a carboxyl group and/or a sulfo group. Since the composition can release SDF-1, a chemokine which is a capable of promoting accumulation of vascular progenitor cells in vivo, in the sustained manner, it can be useful for treatment and/or suppression of symptom progression of ischemic disease or bone disease, as pharmaceutical preparations in various formulations.
    Type: Grant
    Filed: November 6, 2008
    Date of Patent: May 7, 2013
    Assignees: Ono Pharmaceutical Co., Ltd.
    Inventor: Yasuhiko Tabata
  • Patent number: 8414924
    Abstract: An object of the present invention is to establish a cell transplantation method which can markedly improve the survival of grafted pluripotent stem cells and the efficiency of cardiomyocyte regeneration in cell therapy using pluripotent stem cells derived from heart tissue and can treat heart disease further effectively. Specifically, according to the present invention, enhancement in the survival of grafted pluripotent stem cells and significant improvement in the efficiency of cardiomyocyte regeneration are achieved by using, in combination, pluripotent stem cells derived from heart tissue and a hydrogel containing a basic fibroblast growth factor (bFGF) in cell therapy for heart disease.
    Type: Grant
    Filed: October 9, 2008
    Date of Patent: April 9, 2013
    Assignee: Kyoto University
    Inventors: Hidemasa Oh, Naofumi Takehara, Hiroaki Matsubara, Yasuhiko Tabata
  • Publication number: 20120282318
    Abstract: The present invention relates to a sheet for corneal transplants comprising corneal endothelial cells on a gelatin hydrogel, which is obtainable by seeding and culturing corneal endothelial cells on a gelatin hydrogel coated with collagen. The sheet of the present invention is extremely useful as a sheet for corneal transplants not only for its biocompatibility and biodegradability, but also for its high transparency.
    Type: Application
    Filed: August 16, 2010
    Publication date: November 8, 2012
    Applicants: KOYOTO UNIVERSITY, TOHOKU UNIVERSITY
    Inventors: Kohji Nishida, Ryuhei Hayashi, Ryo Watanabe, Yasuhiko Tabata
  • Patent number: 8293819
    Abstract: A method is provided for producing particles which is capable of producing particles in simple and easy steps. The objective is to provide with a high yield particles having a homogeneous particle diameter and a superior dispersibility in liquid. The method includes (1) preparing an aqueous solution containing one or more polymer; and (2) introducing the aqueous solution as droplets into a solvent capable of dissolving water by 1 mass % or more and less than 50 mass % to form the polymer into dispersed particles in the mixture of the aqueous solution and the solvent in the mixture of the aqueous solution and the solvent.
    Type: Grant
    Filed: November 22, 2007
    Date of Patent: October 23, 2012
    Assignees: Canon Kabushiki Kaisha, Medgel Corporation
    Inventors: Kohei Watanabe, Takeshi Miyazaki, Yasuhiko Tabata